Prognostic impact of new permanent pacemaker implantation following transcatheter aortic valve replacement

BackgroundConduction disturbances requiring permanent pacemaker implantation (PPI) are common following transcatheter aortic valve replacement (TAVR). There were conflicting data regarding the impact of new PPI on clinical outcomes after TAVR. ObjectivesThe study sought to evaluate the impact of new PPI on clinical outcomes in patients undergoing TAVR. MethodsThis study was a retrospective analysis of prospectively collected data. Data were from 210 consecutive patients without prior PPI who underwent TAVR due to severe symptomatic aortic stenosis at our center between June 2018 and July 2020. Clinical, echocardiographic, and pacing data were assessed at 30-day, 1- and 2-year follow-up. ResultsNew PPI was required in 35 (16.7%) patients within 30 days after TAVR. The median time from TAVR to PPI was 3 days. The most common indication for PPI was high-degree or complete atrioventricular block. The median follow-up was 798.0 (interquartile range, 669.0-1115.0) days. There were no differences in all-cause mortality (adjusted hazard ratio [HR]: 1.18; 95% confidence interval [CI]: 0.85-2.36; p = 0.415) and cardiovascular mortality (adjusted HR: 0.92; 95% CI: 0.57-1.89; p = 0.609) between groups. However, PPI group had a higher risk of heart failure (HF) rehospitalization (adjusted HR: 1.53; 95% CI: 1.26-2.28; p = 0.027). Echocardiography showed no significant improvement of LVEF over time in patients with PPI. At the latest follow-up, 31.3% of patients exhibited low (& LE;10%) pacing burdens, whereas 28.1% of patients had near constant (>90%) right ventricular pacing. ConclusionsNew PPI within 30 days following TAVR was not associated with an increased risk of all-cause or cardiovascular mortality. However, patients with PPI had a higher risk of HF rehospitalization and lack of LVEF improvement.

Automated summary

This study retrospectively analyzed the clinical outcomes of 210 patients without prior PPI who underwent TAVR at our center between June 2018 and July 2020, and found that 16.7% of patients required new PPI within 30 days after TAVR. Although these patients did not have an increased risk of all-cause mortality and cardiovascular mortality, the PPI group had a higher risk of heart failure rehospitalization and lack of LVEF improvement.